Mindray fights back after fraud allegations hit share price
This article was originally published in Clinica
Executive Summary
Number-one Chinese patient monitoring and IVD firm Mindray Medical International has hit back after a report accused it of hoodwinking investors. The firm’s share price on the New York Stock Exchange dipped 11% to close at $35.61 on 12 December when Ottoman Bay Research first tweeted a link to its report, saying: “Our 103-page deck details why we believe Mindray is a fraud.”